Ticker Details
Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.
IPO Date:	April 14, 2004
Sector:	Healthcare
Industry:	Pharma
Market Cap:	$3.66B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.31 | 2.78%
Avg Daily Range (30 D):	$1.13 | 2.89%
Avg Daily Range (90 D):	$1.56 | 2.68%

Institutional Daily Volume
Avg Daily Volume:	.5M
Avg Daily Volume (30 D):	1.8M
Avg Daily Volume (90 D):	1.42M

Trade Size
Avg Trade Size (Sh.):	98
Avg Trade Size (Sh.) (30 D):	59
Avg Trade Size (Sh.) (90 D):	56

Institutional Trades
Total Institutional Trades:	4,705
Avg Institutional Trade:	$2.91M
Avg Institutional Trade (30 D):	$3.7M
Avg Institutional Trade (90 D):	$4.52M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$4.18M
Avg Closing Trade (30 D):	$10.14M
Avg Closing Trade (90 D):	$10.98M
Avg Closing Volume:	142.2K

News

Feb 25, 2026 @ 2:55 AM uniQure N.V. Securities Fraud Class Action Result ... Source: Kahn Swick & Foti, Llc

Feb 25, 2026 @ 2:48 AM Corcept Therapeutics Incorporated Securities Fraud... Source: Kahn Swick & Foti, Llc

Feb 25, 2026 @ 2:47 AM BellRing Brands, Inc. Securities Fraud Class Actio... Source: Kahn Swick & Foti, Llc

Feb 23, 2026 @ 11:54 PM CORCEPT CLASS ACTION ALERT: Bragar Eagel & Squire,... Source: Bragar Eagel & Squire, P.C.

Feb 23, 2026 @ 7:47 PM CORCEPT THERAPEUTICS INCORPORATED (CORT) INVESTOR ... Source: Bernstein Liebhard Llp

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$1	$.19	$.33
Diluted EPS	$.87	$.16	$.29
Revenue	$741.17M	$207.64M	$194.43M
Gross Profit	$727.78M	$203.04M	$191M
Net Income / Loss	$106.11M	$19.67M	$35.15M
Operating Income / Loss	$65.57M	$10.22M	$26.68M
Cost of Revenue	$13.39M	$4.6M	$3.43M
Net Cash Flow	$-12.15M	$22.39M	$12.93M
PE Ratio	41.49